Bloodless intensive care: A case series and review of Jehovah's Witnesses in ICU

Anaesthesia and Intensive Care

Volumn 32, Issue 6, 2004, Pages 798-803

  Maclaren, G ^a   Anderson, M ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

Anaemia; Bloodless surgery; Erythropoietin; Hyperbaric oxygen; Intensive care; Jehovah's witness: Bloodless medicine

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ARTICLE; AUSTRALIA AND NEW ZEALAND; BLOOD TRANSFUSION; CASE STUDY; CHI SQUARE TEST; CONTROLLED STUDY; CRITICAL ILLNESS; DISEASE SEVERITY; FEMALE; HEMOGLOBIN DETERMINATION; HOSPITAL ADMISSION; HOSPITAL INFORMATION SYSTEM; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; JEHOVAH'S WITNESS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MORTALITY; OUTCOMES RESEARCH; POPULATION RESEARCH; PREVALENCE; RANK SUM TEST; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL;

EID: 11444257021     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0403200611     Document Type: Article

References (35)

1. The Holy Bible. King James edition. Cambridge University Press. Acts 15:28-29.
2. Watchtower Bible and Tract Society. Questions from readers. Watchtower 2000; June 15:29-31.
3. Savarese D, Waitkus H, Stewart F, Callery M. Bloodless medicine and surgery. Intensive Care Med 1999; 14:20-33.
4. Elder L. Why some Jehovah's Witnesses accept blood and conscientiously reject official Watchtower Society blood policy. J Med Ethics 2000; 26:375-380.
5. Carson J, Noveck H, Berlin J, Gould S. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42:812-818.
6. Stewart C. Advanced directives, the right to die and the common law: recent problems with blood transfusions. Melb Univ Law Rev 1999; 23:161-183.
7. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42:114-124.
8. Gannon C, Napolitano L. Severe anaemia after gastrointestinal haemorrhage in a Jehovah's Witness: New treatment strategies. Crit Care Med 2002; 30:1893-1895.
9. McLoughlin P, Cope T, Harrison J. Hyperbaric oxygen therapy in the management of severe acute anaemia in a Jehovah's Witness. Anaesthesia 1999; 54:891-895.
10. Cothren C, Moore E, Offner P, Haenel J, Johnson J. Blood substitute and erythropoietin therapy in a severely injured Jehovah's Witness. N Engl J Med 2002; 346:1097-1098.
11. Moskowitz D, Perelman S, Cousineau K et al. Multidisciplinary management of a Jehovah's Witness patient for the removal of a renal cell carcinoma extending into the right atrium. Can J Anaesth 2002; 49:402-408.
12. Kickler T. Why "bloodless medicine" and how should we do it? Transfusion 2003; 43:550-551.
13. Hardy J, Belisle S, van der Linden P. Combined blood substitute and erythropoietin therapy in a severely injured Jehovah's Witness. N Engl J Med 2002; 347:696-697.
14. Marsh J, Bevan D. Haematological care of the Jehovah's Witness patient. Br J Haematol 2002; 119:25-37.
15. Smoller B, Kruskell M. Phlebotomy for diagnostic laboratory tests in adults: Pattern of use and effect on transfusion requirements. N Engl J Med 1986; 314:1233-1235.
16. Vincent J, Baron J, Reinhart I et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507.
17. Goodnough L, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003; 43:668-676.
18. Corwin H, Gettinger A, Pearl R et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized-controlled trial. JAMA 2002; 288:2827-2835.
19. Carson J. Should patients in intensive care units receive erythropoietin? JAMA 2002; 288:2884-2886.
20. Atabek U, Alvarez R, Pello M et al. Erythropoietin accelerates haemocrit recovery in post-surgical anaemia. Am Surg 1995; 61:74-77.
21. Rohling R, Zimmerman A, Breymann C. Intravenous versus oral iron supplementation from preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin. J Hematother Stem Cell Res 2000; 9:497-500.
22. Macdougall J, Tucker B, Thompson J, Tomson C, Baker L, Raine A. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50:1694-1699.
23. Cope T, Harrison J. The use of hyperbaric oxygen in the management of severe anaemia in a Jehovah's Witness. Anaesthesia 2000; 55:293-294.
24. Reid T. Hb-based oxygen carriers; are we there yet? Transfusion 2003; 43:280-287.
25. Rudolph A, Cliff R, Kwasiborski V, Neville L, Abdullah F, Rabinovici R. Liposome-encapsulated hemoglobin modulates lipopolysaccharide-induced tumor necrosis factor-α production in mice. Crit Care Med 1997; 25:460-468.
26. Klein H. The prospects for red-cell substitutes. N Engl J Med 2000; 342:1666-1668.
27. Mannucci P, Hemostatic drugs. N Engl J Med 1998; 339:245-253.
28. Levi M, Cromleeche M, de Jonge E et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant end points. Lancet 1999; 354:1940-1947.
29. Ray M, O'Brien M. Comparison of ε-aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost. Ann Thorac Surg 2001; 71:838-843.
30. Casati V, Guzzon D, Oppizzi M et al. Transexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg 2000; 120:520-527.
31. Morgan G, Mikhail M, Murray M. Clinical Anesthesiology, 3rd Ed. McGraw Hill 2002:450.
32. Kirkley S. Proposed mechanisms of transfusion-induced immunomodulation. Clin Diagn Lab Immunol 1999; 6:652-657.
33. Vanvakas E, Blajchman M. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97:1180-1195.
34. 1 in supernatants from stored red blood cells inhibits neutrophil locomotion. Blood 2003; 102:1100-1107.
35. Hebert P, Wells G, Blajchman M et al. A multicentre, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417.